Quanterix Corporation, delivering the world’s most sensitive single molecule immunoassay measurement for the benefit of human health, today announced that the Simoa HD-1 Analyzer recently launched by Quanterix uses a “Smart Consumable” designed and manufactured by Sony DADC BioSciences called the Simoa Disc. For use in life science research today and in vitro diagnostics (IVD) markets in the future, the Simoa disc is used to achieve higher levels of sensitivity and precision and is the first diagnostic consumable whose assay technology is based on optical disc formats by Sony DADC.
The Quanterix Simoa Disc is the first diagnostic developed using Sony DADC’s optical disc manufacturing technology. (Photo: Business Wire) Prior to commercializing Simoa, Quanterix needed a high-performance optics consumable that met the requirements of high sensitivity diagnostic testing and lent itself to high volume manufacturing processes at a low cost. Through its relationship with Sony DADC, Quanterix was able to develop a strategy to performing single-molecule isolation and detection in micro arrays of microwells in a low-cost polymeric device configuration. The Quanterix Simoa disc leverages established high-volume polymer replication based on optical disc technology for low cost manufacturing of disposable single molecule arrays.
“Having the opportunity to leverage our excellence in manufacturing microstructured polymer devices in the production of the Simoa Disc is an exciting new venture for us. These discs greatly simplify testing processes and enable the development of fully automated instrumentation for the execution of high throughput samples in single-molecule detection arrays, which are ideal for applications in life science research and in vitro diagnostics,” said Chris Mauracher, Head of Sony DADC’s BioSciences business unit. “The ability to isolate and detect single molecules is at the forefront of next generation analytical techniques. With this advantage, Simoa is already exceeding performance of traditional ELISA assay testing and is a truly disruptive technology. We recognized the company’s endless potential immediately and created these discs exclusively for their use.” “It was critical that we find a partner who not only understands but believes in the promise of Simoa. Sony DADC BioSciences has deep experience with microstructured polymer devices and worked closely with us from the beginning to develop a solution that will grow with us and the changes in the industry,” said Paul Chapman, President and Chief Executive Officer of Quanterix. “The Simoa Disc offers a multitude of advantages for low-cost manufacturing, ease of automation, and instrument development to enable applications in biomarker research and clinical diagnostics. It was the final element needed to ensure consistent quality of results and help bring life-saving technology to market.” The Simoa technology is now commercially available and empowering life science researchers to explore biomarkers and pathways with greater sensitivity and precision, fueling the development of new diagnostic tests and improved treatment of diseases in oncology, neurology, cardiology, and other fields of medicine. To learn more, please visit: quanterix.com/simoa-is-here.